トゥレット症候群（TS）は、チックと呼ばれる反復的、定型的な不随意運動や発声を特徴とする神経疾患です。症状としては、目の瞬きなどの眼球運動、顔のひきつり、肩をすくめること、頭や肩のピクピクなどがあります。その他、鼻を触る、物の匂いを嗅ぐ、腕をバタバタさせる、ホッピングをするなどの症状があります。素因としては、年齢が挙げられます。男性は女性に比べて約3〜4倍トゥレット症候群を発症しやすいと言われています。治療には、抗うつ薬、興奮剤、行動療法などがあります。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tourette Syndrome - Overview
Tourette Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tourette Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tourette Syndrome - Companies Involved in Therapeutics Development
Asarina Pharma AB
Emalex Biosciences Inc
Evero Health Ltd
Noema Pharma AG
Octapharma AG
SOM Biotech SL
Tourette Syndrome - Drug Profiles
bevantolol - Drug Profile
Product Description
Mechanism Of Action
dronabinol + palmidrol - Drug Profile
Product Description
Mechanism Of Action
History of Events
ecopipam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
NOE-105 - Drug Profile
Product Description
Mechanism Of Action
History of Events
sepranolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile
Product Description
Mechanism Of Action
Tourette Syndrome - Dormant Projects
Tourette Syndrome - Discontinued Products
Tourette Syndrome - Product Development Milestones
Featured News & Press Releases
Feb 16, 2022: First patient in for landmark Tourette Syndrome study
Jan 18, 2022: SciSparc advances its phase IIb clinical trial in patients with Tourette syndrome with its proprietary drug candidate SCI-110
Dec 22, 2021: Asarina Pharma receives final approval for landmark phase IIa Tourette study
Dec 08, 2021: Noema Pharma hosting key opinion leader webinar on Stuttering
Nov 10, 2021: Paragon's portfolio company Emalex Biosciences announces positive topline results from phase 2b clinical study evaluating ecopipam for pediatric Tourette syndrome
Sep 16, 2021: Administrative backlog at public authority causes short-term delay in Tourette study
Aug 05, 2021: Noema Pharma initiates phase 2a Allevia study of PDE10A inhibitor NOE-105 in Tourette Syndrome
Jul 26, 2021: SciSparc announces updates regarding its phase IIb study in Tourette Syndrome
Jun 22, 2021: Emalex Biosciences announces completion of patient enrollment in phase 2b clinical trial evaluating Ecopipam (EBS-101) for pediatric patients with Tourette Syndrome
Jun 08, 2021: Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling
May 19, 2021: Asarina Pharma receives approval of CTA for phase IIa Tourette study
Feb 11, 2021: New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome
Feb 10, 2021: SciSparc engages Procaps for development and production of CannAmide and its SCI-110 product candidate
Sep 01, 2020: Emalex Biosciences Phase 2b Tourette Syndrome clinical trial reaches enrollment milestone
Mar 24, 2020: Asarina Pharma to release historic Phase IIb PMDD data on schedule
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Tourette Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Tourette Syndrome - Pipeline by Asarina Pharma AB, 2022
Tourette Syndrome - Pipeline by Emalex Biosciences Inc, 2022
Tourette Syndrome - Pipeline by Evero Health Ltd, 2022
Tourette Syndrome - Pipeline by Noema Pharma AG, 2022
Tourette Syndrome - Pipeline by Octapharma AG, 2022
Tourette Syndrome - Pipeline by SOM Biotech SL, 2022
Tourette Syndrome - Dormant Projects, 2022
Tourette Syndrome - Discontinued Products, 2022
List of Figures
Number of Products under Development for Tourette Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
